New small-cell lung cancer therapy studied
Posted on: Tuesday, 2 June 2009, 14:32 CDT
A U.S.-led international study suggests the combination of two drugs can delay disease progression for patients with advanced non-small cell lung cancer.
Dr. Vincent Miller of the Memorial Sloan-Kettering Cancer Center, one of the study's leaders, said the goal was to determine whether adding erlotinib (Tarceva) to maintenance therapy with bevacizumab (Avastin), an agent commonly used as a component of treatment for advanced non-small cell lung cancer, would delay disease progression.
This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer,
Miller, a thoracic oncologist, said. Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research.
Miller presented the study during the weekend in Orlando, Fla., at the annual meeting of the American Society of Clinical Oncology.
Source: United Press International
Related Articles
- ALIMTA(R) (pemetrexed for injection) First Agent Approved in Europe as Maintenance Therapy for Advanced, Nonsquamous Non-Small Cell Lung Cancer
- Data From Studies of Amrubicin in Small-Cell Lung Cancer Presented at the 2008 American Society of Clinical Oncology Meeting Demonstrate Single Agent Anti-Tumor Activity in Western Patient Population
- AVAX Technologies Announces the Initiation of Its Clinical Study for the Treatment of Patients With Non Small Cell Lung Cancer
- Pivotal Phase III Tarceva Study Published in the New England Journal of Medicine Showed Survival Improvement in Advanced Non-Small Cell Lung Cancer
- Point Therapeutics Presents Positive Results in Phase 2 Talabostat Non-Small Cell Lung Cancer Study
- Biological Variation of Tumor Markers and Its Application in the Detection of Disease Progression in Patients With Non-Small Cell Lung Cancer
- The Impact of Smoking Status on the Behavior and Survival Outcome of Patients With Advanced Non-Small Cell Lung Cancer*: A Retrospective Analysis
- Point Therapeutics Achieves Interim Tumor Response Criteria in Phase 2 Non-Small Cell Lung Cancer Study; Company Advances Talabostat to Second Stage of Study
- A Pragmatic and Successful Approach to Treating Nonsmall-Cell Lung Carcinoma
 |
 |
User Comments (0)
RSS Feeds